Share
BTCS, a Nasdaq-listed company whose main asset is ether, has told the SEC it cannot rule out the liquidation of a roughly $54 million loan on Aave. The loan is backed by the same ether that makes up most of its balance sheet.
What BTCS told regulators
The warning came in a Regulation FD filing dated November 19, 2026. BTCS reported approximately $54 million in debt on the Aave lending protocol, secured by its ether holdings.
Against that debt, the company listed about $111 million in total crypto assets. It valued those holdings at an ETH price of $1,775.
BTCS also reported $18 million in senior secured convertible notes. That is a separate layer of debt on top of the DeFi borrowing.
The company said that because ether’s price is unpredictable, it cannot promise its collateral will avoid liquidation.
A week earlier, the picture looked different. A quarterly filing on November 13 showed about $64.1 million in Aave debt as of November 9.
That debt was backed by 46,676 ETH, worth around $99.3 million at an ETH price of $2,127. The position carried an estimated health factor of about 1.24, with a liquidation threshold near $1,717 per ETH.
So between the two filings, BTCS cut its Aave debt from about $64.1 million to about $54 million. Over the same stretch, the ETH price it used for valuations fell from $2,127 to $1,775.
How an Aave loan gets liquidated
Aave is a decentralized lending protocol. Borrowers post crypto as collateral and take out loans, often in stablecoins, worth less than what they posted.
The crypto and markets news you actually need—every morning.
Daily. Free. Join 34,000+ readers across crypto, finance, and policy.
We respect your privacy. Unsubscribe anytime.
For ether, Aave typically allows a loan-to-value ratio of around 80%. That means a borrower can take out a loan worth up to roughly 80 cents for every dollar of ETH posted.
The health factor is the key number. It measures how much room a position has before liquidation rules kick in. Higher is safer, and as it sinks toward the critical threshold, outside liquidators can step in and sell the collateral to repay the loan.
BTCS’s estimated health factor of about 1.24 on November 9 meant it had some breathing room, but not a lot. The roughly $1,717 liquidation level from that earlier filing applied to the larger $64.1 million debt load, so the current trigger point depends on the position as it stands now.
What the filings show clearly is that BTCS has already had to defend the position. The company has sold ether below its cost basis to keep the health factor above the danger line.
Where the borrowed money went
BTCS has been a steady Aave borrower for a while. Since early 2025, its cumulative stablecoin borrowings on the protocol reached about $152.4 million.
Of that, roughly $89.4 million has already been repaid. The loans mostly fund liquidity pool positions through BTCS’s Imperium DeFi business.
Cash is another pressure point. BTCS reported only around $463,000 in cash at the end of September.
As of mid-November, no liquidations had occurred. BTCS says it continues to watch its borrowing positions and adjust them as prices move.
What this means for ether treasury companies
BTCS is a small company, but its situation is a clean case study in what happens when a public company runs leveraged DeFi strategies on its balance sheet.
The catch is that Aave does not care about quarterly earnings calls or management’s long-term conviction. If the health factor breaks, the protocol’s rules run automatically.
For BTCS shareholders, the key variable is ether’s price relative to the company’s current liquidation point. Every further drop forces a choice: sell more ETH, repay more debt, or accept a higher risk of a forced sale.
There is a second-order issue too. Public companies that hold crypto have to tell investors and regulators about material risks, and BTCS’s filing puts its leverage problem on the record in plain terms.
For the wider market, the filing is a reminder that DeFi leverage is no longer limited to anonymous wallets. Listed companies are now using the same protocols, under the same liquidation rules, with shareholders exposed to the outcome.



